In Vivo Model Development for Inflammatory Bowel Disease

Ace Therapeutics offers comprehensive in vivo animal model development services for Inflammatory Bowel Disease (IBD), providing researchers and pharmaceutical partners with scientifically validated, translational models tailored to accelerate IBD drug discovery and mechanistic studies. Our portfolio encompasses a diverse array of established and custom-developed models, ensuring robust preclinical evaluation of novel therapeutics targeting both ulcerative colitis and Crohn’s disease.

Inflammatory Bowel Disease is a complex, multifactorial disorder requiring preclinical models that faithfully recapitulate its pathogenesis and clinical manifestations. At Ace Therapeutics, we utilize a broad spectrum of species, including Danio rerio (zebrafish), Mus musculus (mouse), and Rattus norvegicus (rat), across multiple strains such as C57BL/6, Balb/c, 129SvEv, Sprague Dawley, and Wistar. These models enable the study of genetic susceptibility, immune dysregulation, microbiome interactions, and environmental triggers relevant to human IBD. Our selection of chemically-induced, genetically modified, dietary, infection-based, and advanced organoid/organ-on-chip models ensures translational relevance and flexibility to address specific research questions.

Chemically-Induced Models

Chemically-induced models are among the most widely used in IBD research and involve the administration of agents such as dextran sulfate sodium (DSS), trinitrobenzene sulfonic acid (TNBS), oxazolone, acetic acid, and indometacin to induce colitis. These agents disrupt the intestinal barrier or provoke immune responses, leading to acute or chronic inflammation mimicking aspects of human ulcerative colitis or Crohn’s disease. Key advantages include rapid onset, reproducibility, and dose-dependent disease severity. These models are ideal for high-throughput screening of therapeutic compounds, evaluating anti-inflammatory efficacy, and studying epithelial barrier function and repair mechanisms.

Genetically Engineered and Immune Cell Transfer Models

Genetic and immune cell transfer models leverage knockout, transgenic, or immunodeficient mice (e.g., Il10-/-, Rag1-/-, Rag2-/-, Card11-/-, Tlr2-/-, Muc2-/-, Abcb1a-/-, Abcb1b-/-) and adoptive transfer of specific T-lymphocyte populations to induce chronic colitis. These models enable the study of genetic predisposition, immune regulatory pathways, and the role of specific gene products in IBD pathogenesis. Advantages include the ability to dissect immune mechanisms, model chronic and relapsing disease, and explore gene-environment interactions. Applications range from mechanistic studies to the evaluation of biologics and cell-based therapies.

Infection-Based and Microbiota-Driven Models

Infection-based models employ bacterial pathogens or manipulation of the gut microbiota to trigger or exacerbate intestinal inflammation. These models reflect the critical role of host-microbe interactions in IBD and can be combined with chemical or genetic predispositions. Humanized microbiota models (e.g., human fecal microbiota-induced colitis in Il10-/- mice) offer translational insight into the contribution of dysbiosis. Advantages include modeling the interplay between pathogens, commensals, and host immunity. These systems are particularly valuable for microbiome-targeted drug development and for studying environmental triggers of IBD.

Dietary and Environmental Models

Dietary models, such as those involving cholate-containing high-fat diets, and environmental stressors (e.g., restraint stress) are used to induce or exacerbate IBD-like pathology. These models are instrumental in investigating the impact of diet, metabolic factors, and stress on gut inflammation and disease progression. Their advantages include relevance to lifestyle-associated disease modifiers and the ability to study gene-environment interactions. Applications include preclinical testing of nutritional interventions and exploration of environmental risk factors.

Organoid and Organ-on-Chip Models

Advanced in vitro systems, including human colonic organoids and organ-on-a-chip platforms, offer human-relevant models for studying intestinal epithelial responses, barrier function, and drug effects under controlled microenvironmental conditions. These models allow for the integration of human cells and complex tissue architecture, enabling detailed mechanistic studies and high-content screening. Advantages include direct translational relevance, reduction in animal usage, and suitability for personalized medicine research.

Ace Therapeutics delivers a turnkey solution for IBD model development, encompassing model selection, induction, monitoring, and comprehensive analysis. Our service includes: (1) Study design consultation and custom protocol development; (2) Induction of IBD using chemical, genetic, immunological, dietary, or infection-based approaches in validated animal strains; (3) Longitudinal monitoring of clinical signs (body weight, stool consistency, occult/gross bleeding, disease activity index); (4) End-point assessments such as colon length, histopathology (inflammation score, ulceration, crypt damage), cytokine profiling (ELISA, multiplex), immune cell phenotyping (flow cytometry, immunohistochemistry), and microbiome analysis (16S rRNA sequencing); (5) Advanced imaging (in vivo and ex vivo), organoid culture, and organ-on-chip analytics as needed. Our analytical capabilities include molecular, cellular, and microbiological endpoints, ensuring comprehensive data generation. Rigorous quality control, ethical compliance, and reproducibility are maintained throughout, with detailed reporting and data interpretation support for clients.

Partnering with Ace Therapeutics provides you with access to a broad, validated platform of IBD models, expert scientific guidance, and end-to-end support from study design to data analysis. Our flexible, client-focused approach ensures that your research objectives are met efficiently and with the highest scientific standards. Whether you are screening new drug candidates, probing disease mechanisms, or seeking translational insight, Ace Therapeutics is your trusted partner for accelerating IBD research. Contact us today to discuss your project and discover how our models can advance your therapeutic development.